FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207583> ?p ?o ?g. }

• W4387207583 endingPage "e341" @default.
• W4387207583 startingPage "e340" @default.
• W4387207583 abstract "Data suggest safety and efficacy of 1.8-2.0 Gy per day radiotherapy (RT) with sequential boost regimens for patients with synchronous prostate and anorectal cancers. Emergence of 25-28 fraction (fx) prostate cancer RT regimens has enabled simultaneously integrated boost techniques to treat the prostate and anorectum (HypoRT), but limited reports exist to support the safety or efficacy of this approach. We aimed to assess oncologic outcomes and patient-reported outcomes (PRO)- and physician-reported adverse effects (AEs) of HypoRT for patients with synchronous prostate and anorectal cancers.This was a retrospective cohort study of patients synchronously diagnosed with prostate and rectal cancer or anal canal squamous cell carcinoma (ASCC) treated with a HypoRT technique and concurrent chemotherapy between 2014-2022. Outcomes included prostate cancer biochemical recurrence (BCR), anorectal cancer recurrence, progression-free (PFS) and overall survival (OS). Acute and late gastrointestinal (GI) and genitourinary (GU) AEs and PRO were prospectively collected using common terminology criteria for AEs (CTCAE) and PRO-CTCAE.Twelve patients were included. Patients had ECOG 0-1; median age was 71 years (51-82). Rectal cancer (n = 11) characteristics included T3 (91%), N1-2 (73%), M0 (73%); 3 had M1a disease suitable for curative-intent treatment. One patient had T2N1M0 ASCC. Prostate cancer risk groups included low (9%), intermediate (45%), and high/very high risk (46%). HypoRT included 45-50 and 67.5 Gy in 25 fx (33%), 46.8-52 and 70.2 Gy in 26 fx (17%), and 44.8-56 and 70 Gy in 28 fx (50%), to the pelvis-anorectum and prostate. Patients with rectal cancer received concurrent capecitabine. Nine (82%) patients with rectal cancer had surgical resection; 1 was R1. The patient with ASCC received concurrent 5-fluorouracil and mitomycin C. Six patients (50%) received androgen suppression. All patients completed treatment successfully but 1 patient with rectal cancer did require hospitalization with treatment break due to GI AEs. Median follow was 60 months (13-103). Oncologic outcomes and AEs are in the table. No patient experienced prostate cancer BCR or ASCC progression. Four of 11 patients with rectal cancer progressed including 3 distant metastases, each amongst initial M1a patients, and 1 local-regrowth in a patient managed non-operatively.HypoRT can effectively be utilized for patients with synchronous prostate and anorectal cancer. Physician assessed AEs compared favorably with prior data, however, further work is needed to understand differences in physician and patient experience. HypoRT may serve as another suitable option in the management of this complex clinical scenario." @default.
• W4387207583 created "2023-09-30" @default.
• W4387207583 creator A5003802438 @default.
• W4387207583 creator A5006321078 @default.
• W4387207583 creator A5008908930 @default.
• W4387207583 creator A5010995181 @default.
• W4387207583 creator A5041365189 @default.
• W4387207583 creator A5050766065 @default.
• W4387207583 creator A5071942279 @default.
• W4387207583 creator A5076744470 @default.
• W4387207583 creator A5083871900 @default.
• W4387207583 creator A5088854603 @default.
• W4387207583 creator A5092972800 @default.
• W4387207583 date "2023-10-01" @default.
• W4387207583 modified "2023-10-17" @default.
• W4387207583 title "“Moderately Hypofractionated” Radiotherapy with a Simultaneously Integrated Boost for Synchronous Treatment of Prostate and Anorectal Cancer" @default.
• W4387207583 doi "https://doi.org/10.1016/j.ijrobp.2023.06.2402" @default.
• W4387207583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785189" @default.
• W4387207583 hasPublicationYear "2023" @default.
• W4387207583 type Work @default.
• W4387207583 citedByCount "0" @default.
• W4387207583 crossrefType "journal-article" @default.
• W4387207583 hasAuthorship W4387207583A5003802438 @default.
• W4387207583 hasAuthorship W4387207583A5006321078 @default.
• W4387207583 hasAuthorship W4387207583A5008908930 @default.
• W4387207583 hasAuthorship W4387207583A5010995181 @default.
• W4387207583 hasAuthorship W4387207583A5041365189 @default.
• W4387207583 hasAuthorship W4387207583A5050766065 @default.
• W4387207583 hasAuthorship W4387207583A5071942279 @default.
• W4387207583 hasAuthorship W4387207583A5076744470 @default.
• W4387207583 hasAuthorship W4387207583A5083871900 @default.
• W4387207583 hasAuthorship W4387207583A5088854603 @default.
• W4387207583 hasAuthorship W4387207583A5092972800 @default.
• W4387207583 hasConcept C121608353 @default.
• W4387207583 hasConcept C126322002 @default.
• W4387207583 hasConcept C126894567 @default.
• W4387207583 hasConcept C133507102 @default.
• W4387207583 hasConcept C143998085 @default.
• W4387207583 hasConcept C197934379 @default.
• W4387207583 hasConcept C2776235491 @default.
• W4387207583 hasConcept C2777793932 @default.
• W4387207583 hasConcept C2779840525 @default.
• W4387207583 hasConcept C2780192828 @default.
• W4387207583 hasConcept C509974204 @default.
• W4387207583 hasConcept C71924100 @default.
• W4387207583 hasConceptScore W4387207583C121608353 @default.
• W4387207583 hasConceptScore W4387207583C126322002 @default.
• W4387207583 hasConceptScore W4387207583C126894567 @default.
• W4387207583 hasConceptScore W4387207583C133507102 @default.
• W4387207583 hasConceptScore W4387207583C143998085 @default.
• W4387207583 hasConceptScore W4387207583C197934379 @default.
• W4387207583 hasConceptScore W4387207583C2776235491 @default.
• W4387207583 hasConceptScore W4387207583C2777793932 @default.
• W4387207583 hasConceptScore W4387207583C2779840525 @default.
• W4387207583 hasConceptScore W4387207583C2780192828 @default.
• W4387207583 hasConceptScore W4387207583C509974204 @default.
• W4387207583 hasConceptScore W4387207583C71924100 @default.
• W4387207583 hasIssue "2" @default.
• W4387207583 hasLocation W43872075831 @default.
• W4387207583 hasLocation W43872075832 @default.
• W4387207583 hasOpenAccess W4387207583 @default.
• W4387207583 hasPrimaryLocation W43872075831 @default.
• W4387207583 hasRelatedWork W1980188241 @default.
• W4387207583 hasRelatedWork W1980245127 @default.
• W4387207583 hasRelatedWork W2038565121 @default.
• W4387207583 hasRelatedWork W2127440557 @default.
• W4387207583 hasRelatedWork W2371104354 @default.
• W4387207583 hasRelatedWork W2372081072 @default.
• W4387207583 hasRelatedWork W2590008096 @default.
• W4387207583 hasRelatedWork W2897445903 @default.
• W4387207583 hasRelatedWork W3082324229 @default.
• W4387207583 hasRelatedWork W3129209394 @default.
• W4387207583 hasVolume "117" @default.
• W4387207583 isParatext "false" @default.
• W4387207583 isRetracted "false" @default.
• W4387207583 workType "article" @default.